A human cell-free translation screen identifies the NT-2 mycotoxin as a ribosomal inhibitor that binds the peptidyl transferase center

This study establishes a human cell-free high-throughput screening platform to identify the NT-2 mycotoxin as a novel ribosomal inhibitor that binds the peptidyl transferase center and induces a dormant state in mammalian protein synthesis.

The Gist

The Big Picture: Finding a "Saboteur" in the Factory

Imagine your body is a massive, bustling factory. Inside every cell, there are tiny machines called ribosomes. These machines are the assembly lines that build proteins, which are the bricks, tools, and workers that keep your body running.

Scientists have long wanted to find new ways to stop these machines, either to understand how they work or to find new medicines. But testing drugs on living cells is like trying to find a leak in a car engine while the car is driving down the highway. It's messy, dangerous, and hard to see exactly what's happening inside the engine.

The Solution: The researchers built a "simulator." Instead of testing on living cells, they took the "engine parts" (ribosomes and machinery) out of human cells and put them in a test tube. This is their Cell-Free Translation Screening (CFTS) platform. It's like taking the assembly line out of the factory and putting it on a lab bench so they can test thousands of chemicals quickly and safely without hurting a living person.

The Hunt: Screening 28,000 Suspects

The team tested about 28,000 different chemical compounds (think of them as 28,000 different keys) to see if any of them could jam the human protein-making machine.

Most of the keys didn't fit. But then, they found a very specific, dangerous key: a natural poison called NT-2.

NT-2 is a mycotoxin, a poison produced by a fungus called Fusarium. You might find this fungus on grains like corn or wheat, especially if the weather gets warmer and wetter. It's a known food safety risk, but until now, scientists didn't fully understand exactly how it attacked human cells.

The Discovery: How NT-2 Works

Once they found NT-2, they wanted to see exactly where it stuck in the machine. They used a super-powerful microscope called Cryo-EM (which is like taking a 3D photo of the machine at the atomic level) to see what was happening.

The Analogy: The Lock and the Key
Imagine the ribosome machine has a very specific "lock" in the middle where the parts are glued together. This is called the Peptidyl Transferase Center (PTC).

• Normal Operation: The machine brings in a new part, glues it to the growing chain, and moves on.
• The Sabotage: NT-2 sneaks into this lock. It fits perfectly, like a piece of gum stuck in a door hinge. It physically blocks the machine from gluing the next part on. The assembly line grinds to a halt.

The Twist: The "Sleeping" Machine
Here is the most interesting part. Usually, when you jam a machine, it just stops. But when NT-2 jams the ribosome, something weird happens: the machine doesn't just stop; it goes into a "dormant" or "sleeping" state.

The researchers found that the machine gets stuck holding onto a specific "sleeping guard" protein called SERBP1. It's as if the machine doesn't just break; it gets locked in a "Do Not Disturb" mode. The factory floor fills up with these idle, sleeping machines, and no new products are made.

Why This Matters: The "Goldilocks" Effect

The paper also tested if NT-2 would hurt other living things, like bacteria (which cause infections) or yeast (used in bread and beer).

• Bacteria: NT-2 did nothing to bacteria. The lock on the bacterial machine is shaped differently, so the key doesn't fit. This is great news because it means this poison might not kill our helpful gut bacteria.
• Yeast: It worked on yeast inside a test tube, but not on living yeast cells. It seems the yeast cell wall is too thick for the poison to get inside.
• Humans: It was very effective at stopping human cells.

This makes NT-2 a "Goldilocks" toxin: it's too weak to hurt bacteria, but just right to hurt humans. This explains why it's dangerous to eat contaminated grain but might not be useful as a broad-spectrum antibiotic.

The Takeaway

1. New Tool: The scientists built a new, high-tech "simulator" (CFTS) that lets them test thousands of chemicals on human protein-making machines without using living people. This is faster and safer than before.
2. New Danger: They identified NT-2, a fungus poison found in grains, as a potent weapon against human protein synthesis.
3. New Mechanism: They discovered that NT-2 doesn't just break the machine; it locks it into a "sleeping" state with a specific protein guard (SERBP1).
4. Future Hope: Understanding exactly how this poison works helps us:
   • Stay Safe: Better monitor our food supply for this specific toxin.
   • Make Medicine: Since this toxin stops protein production so effectively, scientists might be able to tweak its structure to create new drugs that stop cancer cells (which need to make proteins rapidly) without hurting healthy cells.

In short, the researchers took a scary food poison, figured out exactly how it jams the human engine, and showed us a new way to find similar "saboteurs" that could one day become life-saving medicines.

Technical Summary

1. Problem Statement

The discovery of new translation inhibitors is critical for understanding ribosome function and developing therapeutics (e.g., antivirals, anticancer agents). However, current discovery methods face significant limitations:

• Cell-based screens: Often yield false positives/negatives due to compound cytotoxicity, poor cellular uptake, or complex physiological feedback loops that obscure direct target effects. They struggle to distinguish between general growth inhibitors and specific translation modulators.
• Traditional cell-free systems: Systems like rabbit reticulocyte lysates or E. coli extracts lack human-specific context, suffer from tissue-specific artifacts, and are often incompatible with high-throughput screening (HTS) formats or fail to support physiologically relevant post-translational processes.
• Knowledge Gap: While natural toxins like trichothecenes are known to inhibit translation, many specific variants (like NT-2) remain uncharacterized in human systems, posing potential risks to food safety and human health.

2. Methodology

The authors developed and utilized a novel Human Cell-Free Translation Screening (CFTS) platform to overcome these barriers.

• Platform Development:
  • Source Material: Used cytoplasmically enriched HeLa S3 cell lysates prepared via dual-centrifugation. This preserves human-specific translation features (cap-dependence, poly(A) sensitivity) while providing scalable material.
  • Assay Format: A 384-well high-throughput format using 5 µL reaction volumes.
  • Readout: Quantitative luminescence measurement of Renilla luciferase (RLuc) translation from capped and polyadenylated mRNA reporters.
  • Optimization: Validated stability of frozen/thawed lysates, signal stability over 90 minutes, and assay robustness (Z' factor of 0.82).
• Screening Campaign:
  • Screened ~28,000 small molecules from six diverse libraries (FDA-approved drugs, kinase inhibitors, PPI inhibitors, natural product-inspired, chemically diverse, and natural products).
  • Primary hits (score > 0.6) were subjected to dose-response validation (30 nM – 100 µM).
  • False Positive Elimination: Used Western blotting to distinguish true translation inhibitors from compounds that merely inhibit luciferase enzyme activity.
• Mechanistic Characterization:
  • In Vitro/In Vivo Validation: Tested potency in human (HEK293T), yeast, and bacterial (E. coli) systems using puromycin incorporation, polysome profiling, and growth curves.
  • Structural Biology: Employed single-particle Cryo-Electron Microscopy (Cryo-EM) on human 80S ribosomes purified from NT-2-treated cells. Achieved a resolution of 1.76 Å.
  • State Analysis: Classified ribosomal particles to identify conformational states (e.g., eEF2 binding, SERBP1 association).

3. Key Contributions

1. Establishment of a Scalable Human CFTS Platform: The first robust, high-throughput cell-free screening platform using human lysates that bypasses cellular uptake barriers and cytotoxicity, allowing for the direct identification of translation modulators.
2. Identification of NT-2 as a Novel Inhibitor: Discovered NT-2 (15-deacetyl-neosolaniol), a trichothecene mycotoxin from Fusarium sporotrichioides, as a potent, previously uncharacterized inhibitor of human protein synthesis.
3. Atomic-Level Structural Insight: Solved the structure of NT-2 bound to the human 60S ribosomal subunit at 1.76 Å, revealing its precise binding mode in the Peptidyl Transferase Center (PTC).
4. Discovery of a Dormant Ribosome State: Linked NT-2 inhibition to the accumulation of a specific, inactive ribosome state characterized by the simultaneous presence of eEF2 and SERBP1.

4. Key Results

• Screening Performance:

  • The CFTS successfully identified known inhibitors (cyclohexide, puromycin, T-2 toxin) and novel hits.
  • NT-2 was identified with a hit score of 0.73. Dose-response assays confirmed it as a bona fide translation inhibitor with an IC50 of 4.1 µM in human lysates.
  • Validation via Western blot confirmed that luminescence reduction correlated with decreased protein synthesis, ruling out luciferase-specific artifacts.

• Biological Specificity:

  • Human Cells: NT-2 showed high potency in living HEK293T cells (IC50 = 135 nM), suggesting enhanced intracellular accumulation or uptake compared to lysates.
  • Bacteria: NT-2 had no effect on E. coli growth or E. coli S30 extracts, confirming strict eukaryotic specificity.
  • Yeast: NT-2 inhibited translation in S. cerevisiae lysates but did not affect yeast cell growth, likely due to the yeast cell wall acting as a barrier to uptake.

• Mechanism of Action (Cryo-EM):

  • Binding Site: NT-2 binds directly to the Peptidyl Transferase Center (PTC) of the 60S subunit, specifically occupying the A-site cleft.
  • Interactions: The structure revealed hydrogen bonds between the NT-2 epoxide and hydroxyl groups and specific rRNA nucleotides (U4450, U4446, C4398, G3907, A4449).
  • Selectivity: The lack of activity in bacteria is explained by structural divergence in the prokaryotic PTC, which cannot accommodate NT-2.
  • Comparison: While NT-2 shares the PTC binding pocket with other trichothecenes (T-2, deoxynivalenol), its unique substitution pattern (C-8 hydroxyl, 4β-acetoxy) allows it to bind without steric clash with the P-site tRNA, unlike some larger analogs.

• Ribosome State & Dormancy:

  • Polysome profiling showed NT-2 treatment causes a collapse of polysomes and accumulation of 80S monosomes, similar to the early elongation inhibitor harringtonine.
  • Cryo-EM Classification: NT-2 treatment led to a ~4-fold enrichment of a specific ribosome state: 80S complexes bound to eEF2 and SERBP1 (an RNA-binding protein).
  • This "dormant" state involves SERBP1 occluding the mRNA channel and stabilizing the ribosome-eEF2 complex, preventing productive elongation. This state was not observed when NT-2 was added to purified ribosomes in vitro, highlighting the necessity of studying inhibitors in a physiological context.

5. Significance

• Toxicology & Food Safety: The study identifies NT-2 as a potent environmental threat to human health. As a contaminant from Fusarium in global grain supplies, its ability to specifically inhibit mammalian translation at low concentrations underscores the need for better monitoring of trichothecene variants in food chains.
• Therapeutic Potential: The discovery of NT-2's specific binding mode and its ability to induce a dormant ribosome state offers a new scaffold for developing anticancer or antiviral drugs that target the human ribosome without affecting bacterial microbiota.
• Methodological Advancement: The CFTS platform demonstrates that human cell-free systems can outperform traditional cell-based screens in identifying specific translation modulators, providing a blueprint for future drug discovery efforts targeting protein synthesis.
• Biological Insight: The findings expand the understanding of ribosome regulation, linking chemical inhibition to the formation of SERBP1-stabilized dormant ribosomes, a mechanism previously associated with stress responses (e.g., cold shock, nutrient starvation).